Trial · NCT07299331
Zanubrutinib, Rituximab, and Lenalidomide in the First-Line Treatment of Marginal Zone Lymphoma
NCT07299331, Not applicable, Not yet recruiting, Zhengzhou University
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Zanubrutinib, Rituximab, and Lenalidomide in the First-Line Treatment of Marginal Zone Lymphoma. Trials, record NCT07299331. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07299331
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Zanubrutinib, Rituximab, and Lenalidomide in the First-Line Treatment of Marginal Zone Lymphoma
- NCT number
- NCT07299331
- Status
- Not yet recruiting
- Phases
- Not applicable
- Enrollment
- 50 participants, estimated
- Lead sponsor
- Zhengzhou University
- Conditions
- Marginal Zone Lymphoma(MZL)
- Interventions
- Zanubrutinib, Rituximab, and Lenalidomide as first-line treatment for Marginal Zone Lymphoma, Zanubrutinib, Rituximab, and Lenalidomide as the primary treatment for Marginal Zone Lymphoma
- First posted
- 2025-12-23
- Last updated
- 2025-12-23
Source ClinicalTrials.gov
Registered outcomes7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | CRR | 2 years | Complete remission rate |
| Secondary | ORR | 2 years | Objective response rate |
| Secondary | 2 year-progress free survival rate | 2 years | the time from the start of treatment to the time when the patient has progressed on the disease or dies due to any cause in 2 years. |
| Secondary | TTR | From randomization up to 24 months post-randomization | Time from randomization to the first documentation of Complete Response (CR) or Partial Response (PR) , verified by computed tomography (CT) and positron emission tomography (PET)-CT at least 6 weeks apart |
| Secondary | DoR | From the date of first confirmed CR/PR up to 24 months post-confirmed response | The interval from the date of first confirmed OR to the first evidence of progressive disease or death from any cause |
| Secondary | OS | From randomization up to 24 months post-randomization | The time from the date of randomization to the date of death from any cause |
| Secondary | Incidence rate of adverse events | 2 years |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07299331
GET https://conductscience.org/api/trials/v1/NCT07299331/registered